Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.455 +0.125 (+2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Aligns With Industry Call to Fix “Broken” Biotech Model
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer
Via Investor Brand Network
Topics Artificial Intelligence
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
From Lantern Pharma Inc.
Via Business Wire
MissionIRNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool
Via Investor Brand Network
Topics Artificial Intelligence
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials, Expands AI Platform
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
Via Investor Brand Network
Topics Artificial Intelligence
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.